Supernus Pharmaceuticals Research and Development Expenses 2011-2024 | SUPN
Supernus Pharmaceuticals research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Supernus Pharmaceuticals Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$92 |
| 2022 |
$75 |
| 2021 |
$90 |
| 2020 |
$76 |
| 2019 |
$69 |
| 2018 |
$89 |
| 2017 |
$50 |
| 2016 |
$43 |
| 2015 |
$29 |
| 2014 |
$20 |
| 2013 |
$17 |
| 2012 |
$24 |
| 2011 |
$31 |
| 2010 |
$35 |
Supernus Pharmaceuticals Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-09-30 |
$29 |
| 2024-06-30 |
$26 |
| 2024-03-31 |
$25 |
| 2023-12-31 |
$23 |
| 2023-09-30 |
$23 |
| 2023-06-30 |
$24 |
| 2023-03-31 |
$21 |
| 2022-12-31 |
$18 |
| 2022-09-30 |
$20 |
| 2022-06-30 |
$16 |
| 2022-03-31 |
$21 |
| 2021-12-31 |
$21 |
| 2021-09-30 |
$20 |
| 2021-06-30 |
$15 |
| 2021-03-31 |
$34 |
| 2020-12-31 |
$18 |
| 2020-09-30 |
$17 |
| 2020-06-30 |
$22 |
| 2020-03-31 |
$19 |
| 2019-12-31 |
$20 |
| 2019-09-30 |
$17 |
| 2019-06-30 |
$17 |
| 2019-03-31 |
$15 |
| 2018-12-31 |
$30 |
| 2018-09-30 |
$20 |
| 2018-06-30 |
$20 |
| 2018-03-31 |
$19 |
| 2017-12-31 |
$16 |
| 2017-09-30 |
$13 |
| 2017-06-30 |
$11 |
| 2017-03-31 |
$10 |
| 2016-12-31 |
$13 |
| 2016-09-30 |
$8 |
| 2016-06-30 |
$11 |
| 2016-03-31 |
$11 |
| 2015-12-31 |
$9 |
| 2015-09-30 |
$9 |
| 2015-06-30 |
$7 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$6 |
| 2014-09-30 |
$5 |
| 2014-06-30 |
$5 |
| 2014-03-31 |
$4 |
| 2013-12-31 |
$5 |
| 2013-09-30 |
$4 |
| 2013-06-30 |
$4 |
| 2013-03-31 |
$5 |
| 2012-12-31 |
$5 |
| 2012-09-30 |
$8 |
| 2012-06-30 |
$5 |
| 2012-03-31 |
$5 |
| 2011-12-31 |
$8 |
| 2011-09-30 |
$8 |
| 2011-06-30 |
$7 |
| 2011-03-31 |
$7 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
